Evaluation of the pediatric Crohn disease activity index: A prospective multicenter experience

Jeffrey Hyams, James Markowitz, Anthony Otley, Joel Rosh, David Mack, Athos Bousvaros, Subra Kugathasan, M. Pfefferkorn, Vasundhara Tolia, Jonathan Evans, William Treem, Robert Wyllie, Robert Rothbaum, J. Del Rosario, Aubrey Katz, Adam Mezoff, M. Oliva-Hemker, Trudy Lerer, Anne Griffiths

Research output: Contribution to journalArticle

201 Citations (Scopus)

Abstract

Background and Objectives: Longitudinal assessment of disease activity is necessary for studies of therapeutic intervention in children with Crohn disease. The Pediatric Crohn Disease Activity Index (PCDAI) was developed a decade ago for such a purpose, but it function has only been examined in a small number of studies with a limited number of patients. The primary objectives of the present study were to develop cut scores reflecting disease activity as determined by physician global assessment (PGA) and to evaluate the responsiveness of the PCDAI to changes in patient condition after therapeutic interventions. Methods: Data were derived from a prospective database of newly diagnosed children with inflammatory bowel disease established in 2002 at 18 pediatric gastroenterology centers in the United States and Canada. At diagnosis, at 30 days and 3 months after diagnosis, and quarterly thereafter, children (<16 years of age) with Crohn disease had disease assessment performed by PGA and PCDAI. Disease management was provided according to the dictates of the attending gastroenterologist and not by predetermined protocol. Results: 181 patients had concomitant PGA and PCDAI performed at diagnosis, and 95 of these had similar assessment at short-term follow up. Mean ± SD PCDAI scores for mild, moderate, and severe disease by PGA at diagnosis were 19.5 ± 10.4, 32.2 ± 12.7, and 47.8 ± 14.9, respectively (P < 0.001 for all comparisons). Mean ± SD PCDAI for inactive disease after treatment was 5.2 ± 5.4. Receiver operating characteristic (ROC) curve analysis suggested that: 1) activity of moderate/severe disease was best reflected by a PCDAI of ≥30 points, 2) clinical response (moderate/severe disease improving to mild/inactive) was best reflected by a decrease in PCDAI of ≥12.5 points, and 3) a PCDAI < 10 best reflected inactive disease. Conclusions: PCDAI scores accurately reflect disease activity as assessed by physician global assessment. A PCDAI score of ≥30 has acceptable sensitivity and specificity to indicate disease of moderate/severe activity. A PCDAI decrease of 12.5 points or greater following therapeutic intervention accurately reflects a clinically significant response. The PCDAI is an appropriate tool for intervention trials in Crohn disease in children.

Original languageEnglish (US)
Pages (from-to)416-421
Number of pages6
JournalJournal of pediatric gastroenterology and nutrition
Volume41
Issue number4
DOIs
StatePublished - Oct 1 2005

Fingerprint

Physicians
Crohn Disease
Pediatric Crohn's disease
Gastroenterology
Therapeutics
Disease Management
Inflammatory Bowel Diseases
ROC Curve
Canada
Databases
Pediatrics
Sensitivity and Specificity

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Gastroenterology

Cite this

Hyams, Jeffrey ; Markowitz, James ; Otley, Anthony ; Rosh, Joel ; Mack, David ; Bousvaros, Athos ; Kugathasan, Subra ; Pfefferkorn, M. ; Tolia, Vasundhara ; Evans, Jonathan ; Treem, William ; Wyllie, Robert ; Rothbaum, Robert ; Del Rosario, J. ; Katz, Aubrey ; Mezoff, Adam ; Oliva-Hemker, M. ; Lerer, Trudy ; Griffiths, Anne. / Evaluation of the pediatric Crohn disease activity index : A prospective multicenter experience. In: Journal of pediatric gastroenterology and nutrition. 2005 ; Vol. 41, No. 4. pp. 416-421.
@article{26c4dfed1bf04ae7bbe3c657e3d55c64,
title = "Evaluation of the pediatric Crohn disease activity index: A prospective multicenter experience",
abstract = "Background and Objectives: Longitudinal assessment of disease activity is necessary for studies of therapeutic intervention in children with Crohn disease. The Pediatric Crohn Disease Activity Index (PCDAI) was developed a decade ago for such a purpose, but it function has only been examined in a small number of studies with a limited number of patients. The primary objectives of the present study were to develop cut scores reflecting disease activity as determined by physician global assessment (PGA) and to evaluate the responsiveness of the PCDAI to changes in patient condition after therapeutic interventions. Methods: Data were derived from a prospective database of newly diagnosed children with inflammatory bowel disease established in 2002 at 18 pediatric gastroenterology centers in the United States and Canada. At diagnosis, at 30 days and 3 months after diagnosis, and quarterly thereafter, children (<16 years of age) with Crohn disease had disease assessment performed by PGA and PCDAI. Disease management was provided according to the dictates of the attending gastroenterologist and not by predetermined protocol. Results: 181 patients had concomitant PGA and PCDAI performed at diagnosis, and 95 of these had similar assessment at short-term follow up. Mean ± SD PCDAI scores for mild, moderate, and severe disease by PGA at diagnosis were 19.5 ± 10.4, 32.2 ± 12.7, and 47.8 ± 14.9, respectively (P < 0.001 for all comparisons). Mean ± SD PCDAI for inactive disease after treatment was 5.2 ± 5.4. Receiver operating characteristic (ROC) curve analysis suggested that: 1) activity of moderate/severe disease was best reflected by a PCDAI of ≥30 points, 2) clinical response (moderate/severe disease improving to mild/inactive) was best reflected by a decrease in PCDAI of ≥12.5 points, and 3) a PCDAI < 10 best reflected inactive disease. Conclusions: PCDAI scores accurately reflect disease activity as assessed by physician global assessment. A PCDAI score of ≥30 has acceptable sensitivity and specificity to indicate disease of moderate/severe activity. A PCDAI decrease of 12.5 points or greater following therapeutic intervention accurately reflects a clinically significant response. The PCDAI is an appropriate tool for intervention trials in Crohn disease in children.",
author = "Jeffrey Hyams and James Markowitz and Anthony Otley and Joel Rosh and David Mack and Athos Bousvaros and Subra Kugathasan and M. Pfefferkorn and Vasundhara Tolia and Jonathan Evans and William Treem and Robert Wyllie and Robert Rothbaum and {Del Rosario}, J. and Aubrey Katz and Adam Mezoff and M. Oliva-Hemker and Trudy Lerer and Anne Griffiths",
year = "2005",
month = "10",
day = "1",
doi = "10.1097/01.mpg.0000183350.46795.42",
language = "English (US)",
volume = "41",
pages = "416--421",
journal = "Journal of Pediatric Gastroenterology and Nutrition",
issn = "0277-2116",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

Hyams, J, Markowitz, J, Otley, A, Rosh, J, Mack, D, Bousvaros, A, Kugathasan, S, Pfefferkorn, M, Tolia, V, Evans, J, Treem, W, Wyllie, R, Rothbaum, R, Del Rosario, J, Katz, A, Mezoff, A, Oliva-Hemker, M, Lerer, T & Griffiths, A 2005, 'Evaluation of the pediatric Crohn disease activity index: A prospective multicenter experience', Journal of pediatric gastroenterology and nutrition, vol. 41, no. 4, pp. 416-421. https://doi.org/10.1097/01.mpg.0000183350.46795.42

Evaluation of the pediatric Crohn disease activity index : A prospective multicenter experience. / Hyams, Jeffrey; Markowitz, James; Otley, Anthony; Rosh, Joel; Mack, David; Bousvaros, Athos; Kugathasan, Subra; Pfefferkorn, M.; Tolia, Vasundhara; Evans, Jonathan; Treem, William; Wyllie, Robert; Rothbaum, Robert; Del Rosario, J.; Katz, Aubrey; Mezoff, Adam; Oliva-Hemker, M.; Lerer, Trudy; Griffiths, Anne.

In: Journal of pediatric gastroenterology and nutrition, Vol. 41, No. 4, 01.10.2005, p. 416-421.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Evaluation of the pediatric Crohn disease activity index

T2 - A prospective multicenter experience

AU - Hyams, Jeffrey

AU - Markowitz, James

AU - Otley, Anthony

AU - Rosh, Joel

AU - Mack, David

AU - Bousvaros, Athos

AU - Kugathasan, Subra

AU - Pfefferkorn, M.

AU - Tolia, Vasundhara

AU - Evans, Jonathan

AU - Treem, William

AU - Wyllie, Robert

AU - Rothbaum, Robert

AU - Del Rosario, J.

AU - Katz, Aubrey

AU - Mezoff, Adam

AU - Oliva-Hemker, M.

AU - Lerer, Trudy

AU - Griffiths, Anne

PY - 2005/10/1

Y1 - 2005/10/1

N2 - Background and Objectives: Longitudinal assessment of disease activity is necessary for studies of therapeutic intervention in children with Crohn disease. The Pediatric Crohn Disease Activity Index (PCDAI) was developed a decade ago for such a purpose, but it function has only been examined in a small number of studies with a limited number of patients. The primary objectives of the present study were to develop cut scores reflecting disease activity as determined by physician global assessment (PGA) and to evaluate the responsiveness of the PCDAI to changes in patient condition after therapeutic interventions. Methods: Data were derived from a prospective database of newly diagnosed children with inflammatory bowel disease established in 2002 at 18 pediatric gastroenterology centers in the United States and Canada. At diagnosis, at 30 days and 3 months after diagnosis, and quarterly thereafter, children (<16 years of age) with Crohn disease had disease assessment performed by PGA and PCDAI. Disease management was provided according to the dictates of the attending gastroenterologist and not by predetermined protocol. Results: 181 patients had concomitant PGA and PCDAI performed at diagnosis, and 95 of these had similar assessment at short-term follow up. Mean ± SD PCDAI scores for mild, moderate, and severe disease by PGA at diagnosis were 19.5 ± 10.4, 32.2 ± 12.7, and 47.8 ± 14.9, respectively (P < 0.001 for all comparisons). Mean ± SD PCDAI for inactive disease after treatment was 5.2 ± 5.4. Receiver operating characteristic (ROC) curve analysis suggested that: 1) activity of moderate/severe disease was best reflected by a PCDAI of ≥30 points, 2) clinical response (moderate/severe disease improving to mild/inactive) was best reflected by a decrease in PCDAI of ≥12.5 points, and 3) a PCDAI < 10 best reflected inactive disease. Conclusions: PCDAI scores accurately reflect disease activity as assessed by physician global assessment. A PCDAI score of ≥30 has acceptable sensitivity and specificity to indicate disease of moderate/severe activity. A PCDAI decrease of 12.5 points or greater following therapeutic intervention accurately reflects a clinically significant response. The PCDAI is an appropriate tool for intervention trials in Crohn disease in children.

AB - Background and Objectives: Longitudinal assessment of disease activity is necessary for studies of therapeutic intervention in children with Crohn disease. The Pediatric Crohn Disease Activity Index (PCDAI) was developed a decade ago for such a purpose, but it function has only been examined in a small number of studies with a limited number of patients. The primary objectives of the present study were to develop cut scores reflecting disease activity as determined by physician global assessment (PGA) and to evaluate the responsiveness of the PCDAI to changes in patient condition after therapeutic interventions. Methods: Data were derived from a prospective database of newly diagnosed children with inflammatory bowel disease established in 2002 at 18 pediatric gastroenterology centers in the United States and Canada. At diagnosis, at 30 days and 3 months after diagnosis, and quarterly thereafter, children (<16 years of age) with Crohn disease had disease assessment performed by PGA and PCDAI. Disease management was provided according to the dictates of the attending gastroenterologist and not by predetermined protocol. Results: 181 patients had concomitant PGA and PCDAI performed at diagnosis, and 95 of these had similar assessment at short-term follow up. Mean ± SD PCDAI scores for mild, moderate, and severe disease by PGA at diagnosis were 19.5 ± 10.4, 32.2 ± 12.7, and 47.8 ± 14.9, respectively (P < 0.001 for all comparisons). Mean ± SD PCDAI for inactive disease after treatment was 5.2 ± 5.4. Receiver operating characteristic (ROC) curve analysis suggested that: 1) activity of moderate/severe disease was best reflected by a PCDAI of ≥30 points, 2) clinical response (moderate/severe disease improving to mild/inactive) was best reflected by a decrease in PCDAI of ≥12.5 points, and 3) a PCDAI < 10 best reflected inactive disease. Conclusions: PCDAI scores accurately reflect disease activity as assessed by physician global assessment. A PCDAI score of ≥30 has acceptable sensitivity and specificity to indicate disease of moderate/severe activity. A PCDAI decrease of 12.5 points or greater following therapeutic intervention accurately reflects a clinically significant response. The PCDAI is an appropriate tool for intervention trials in Crohn disease in children.

UR - http://www.scopus.com/inward/record.url?scp=26044457921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26044457921&partnerID=8YFLogxK

U2 - 10.1097/01.mpg.0000183350.46795.42

DO - 10.1097/01.mpg.0000183350.46795.42

M3 - Article

C2 - 16205508

AN - SCOPUS:26044457921

VL - 41

SP - 416

EP - 421

JO - Journal of Pediatric Gastroenterology and Nutrition

JF - Journal of Pediatric Gastroenterology and Nutrition

SN - 0277-2116

IS - 4

ER -